{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:38:39Z","timestamp":1792629519580,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.lungcan.2025.108664","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T12:18:57Z","timestamp":1752581937000},"page":"108664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet"],"prefix":"10.1016","volume":"206","author":[{"given":"Astrid","family":"Paulus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6633-5749","authenticated-orcid":false,"given":"Marius","family":"Zemaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-8932","authenticated-orcid":false,"given":"Saulius","family":"Cicenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanete","family":"Zvirbule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6725-7562","authenticated-orcid":false,"given":"Annika","family":"Sanfridson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Rydberg","family":"Millrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Magnusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nedjad","family":"Losic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9541-8644","authenticated-orcid":false,"given":"Dominique","family":"Tersago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9911-7371","authenticated-orcid":false,"given":"Ignacio","family":"Garcia-Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Thorsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis G.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.lungcan.2025.108664_b0005","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108664_b0010","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/OP.24.00177","article-title":"Therapy for Stage IV non-small cell lung cancer with and without driver alterations: ASCO living guideline clinical insights","volume":"20","author":"Owen","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.lungcan.2025.108664_b0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108664_b0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108664_b0025","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/JTO.0b013e3182037b76","article-title":"The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer","volume":"6","author":"Bremnes","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108664_b0030","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-17-1366","article-title":"Tumor-stroma IL1beta-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108664_b0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/imr.12614","article-title":"IL-1 and IL-1 regulatory pathways in cancer progression and therapy","volume":"281","author":"Mantovani","year":"2018","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108664_b0040","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"issue":"52","key":"10.1016\/j.lungcan.2025.108664_b0045","doi-asserted-by":"crossref","first-page":"85876","DOI":"10.18632\/oncotarget.13042","article-title":"Correlation between serum IL-1beta and miR-144-3p as well as their prognostic values in LUAD and LUSC patients","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108664_b0050","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.celrep.2016.05.085","article-title":"Neutrophil-derived IL-1beta impairs the efficacy of NF-kappaB Inhibitors against lung cancer","volume":"16","author":"McLoed","year":"2016","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108664_b0055","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-022-01286-4","article-title":"Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer","volume":"15","author":"Zhang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lungcan.2025.108664_b0060","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.biopha.2018.07.099","article-title":"Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer","volume":"107","author":"Zheng","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lungcan.2025.108664_b0065","unstructured":"Genotype-Tissue Expression (GTEx) Project Portal. https:\/\/gtexportal.org\/home\/."},{"key":"10.1016\/j.lungcan.2025.108664_b0070","unstructured":"National Cancer Institute. Center for Cancer Genomics. The Cancer Genome Atlas Program (TCGA). Available from https:\/\/www.cancer.gov\/ccg\/research\/genome-sequencing\/tcga."},{"key":"10.1016\/j.lungcan.2025.108664_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104200","article-title":"Interleukin-1 receptor accessory protein (IL-1RAP): a magic bullet candidate for immunotherapy of human malignancies","volume":"193","author":"Zarezadeh Mehrabadi","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"23","key":"10.1016\/j.lungcan.2025.108664_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314918","article-title":"IL-1RAP, a key therapeutic target in cancer","volume":"23","author":"Frenay","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.lungcan.2025.108664_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411547","article-title":"Comprehensive review: unveiling the pro-oncogenic roles of IL-1ss and PD-1\/PD-L1 in NSCLC development and targeting their pathways for clinical management","volume":"24","author":"Castillo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2025.108664_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.779100","article-title":"Molecular basis of selective cytokine signaling inhibition by antibodies targeting a shared receptor","volume":"12","author":"Fields","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108664_b0095","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00262-022-03277-3","article-title":"Blockade of IL-1alpha and IL-1beta signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy","volume":"72","author":"Rydberg Millrud","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108664_b0100","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41416-021-01657-7","article-title":"First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours","volume":"126","author":"Robbrecht","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"18","key":"10.1016\/j.lungcan.2025.108664_b0105","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.lungcan.2025.108664_b0110","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1158\/1078-0432.CCR-24-0645","article-title":"Efficacy and safety of the anti-IL1RAP antibody nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in patients with advanced\/metastatic pancreatic cancer","volume":"30","author":"Van Cutsem","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108664_b0115","doi-asserted-by":"crossref","unstructured":"R.B. Cohen, A. Jimeno, J. Hreno, L. Sun, M. Wallen-Ohman, C.R. Millrud, A. Sanfridson, I. Garcia-Ribas, Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL-1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors, Invest. New Drugs (2025).","DOI":"10.1007\/s10637-025-01538-3"},{"issue":"21","key":"10.1016\/j.lungcan.2025.108664_b0120","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung canc","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.lungcan.2025.108664_b0125","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.lungcan.2025.108664_b0130","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.2012.48.1911","article-title":"Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2","volume":"31","author":"Zukin","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108664_b0135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.lungcan.2013.01.008","article-title":"Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial","volume":"80","author":"Gervais","year":"2013","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108664_b0140","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009523","article-title":"Blocking IL1RAP on cancer-associated fibroblasts in pancreatic ductal adenocarcinoma suppresses IL-1-induced neutrophil recruitment","volume":"12","author":"Hansen","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108664_b0145","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2088467","article-title":"Immune suppressive function of IL-1alpha release in the tumor microenvironment regulated by calpain 1","volume":"11","author":"Lin","year":"2022","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108664_b0150","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1200\/JCO.23.00980","article-title":"Canakinumab versus placebo in combination with first-line pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer: results from the CANOPY-1 trial","volume":"42","author":"Tan","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108664_b0155","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","article-title":"Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer","volume":"13","author":"Park","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108664_b0160","first-page":"2649","article-title":"Del Barco-Morillo, Response to platinum-based therapies in second-line after immunotherapy in advanced or metastatic non-small-cell lung cancer PD-L1 >\/=50, Transl Lung","volume":"13","author":"Olivares-Hernandez","year":"2024","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108664_b0165","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.3390\/curroncol30060402","article-title":"Real-world outcomes of Stage IV NSCLC with PD-L1 >\/= 50% treated with first-line pembrolizumab: uptake of second-line systemic therapy","volume":"30","author":"Rittberg","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lungcan.2025.108664_b0170","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","article-title":"Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"112","author":"Schvartsman","year":"2017","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108664_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203070","article-title":"Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: a retrospective study","volume":"13","author":"Yano","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108664_b0180","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108664_b0185","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1038\/s41467-021-25432-7","article-title":"Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity","volume":"12","author":"Cindy Yang","year":"2021","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108664_b0190","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/cvr\/cvae046","article-title":"Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation","volume":"120","author":"Mulholland","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lungcan.2025.108664_b0195","unstructured":"M.R.K. Raja, G. Gupta, G. Atkinson, K. Kathrein, A. Armstrong, M. Gower, I. Roninson, E. Broude, M. Chen, H. Ji, C. Lim, H. Wang, D. Fan, P. Xu, J. Li, G. Zhou, H. Chen, Host-derived Interleukin 1alpha induces an immunosuppressive tumor microenvironment via regulating monocyte-to-macrophage differentiation, bioRxiv (2024)."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108664_b0200","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1073\/pnas.1812266115","article-title":"Blocking IL-1beta reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation","volume":"116","author":"Kaplanov","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2025.108664_b0205","doi-asserted-by":"crossref","unstructured":"R. Cohen, A. Jimeno, J. Hreno, L. Sun, M. Wall\u00e9n \u00d6hman, A. Sanfridson, N. Losic, D. Tersago, Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors. 1012P. ESMO Congress 2024. 13-17 September, 2024. Barcelona, Spain.","DOI":"10.1016\/j.annonc.2024.08.1071"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225005562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225005562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:27:33Z","timestamp":1778473653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225005562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":41,"alternative-id":["S0169500225005562"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108664","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108664"}}